Cellyrix Therapeutics
TargetingTumor Heterogeneity
StartupCellyrix Therapeutics is a Rehovot-based startup in the Health Tech & Life Sciences sector, established in 2024. TargetingTumor Heterogeneity. Cellyrix Therapeutics was founded by Mordechai Applebaum, Dganit Bar, Avishai Gavish. The company has 1-10 employees. Core technologies: Artificial Intelligence, Generative AI, Biologicals, Molecules.
The company follows a B2B business model. Product stage: R&D.
- StagePre-Funding
- ProductR&D
- ModelB2B
- Employees1-10
- HQRehovot
- DistrictCenter District
- Last RoundUndisclosed
Mordechai ApplebaumCEO
Dganit BarCSO
Avishai GavishChief Business Consultant
What does Cellyrix Therapeutics do?
At Cellyrix, we are on a mission to introduce a new modality into cancer treatment by harnessing the power of cutting-edge technologies. Tumor heterogeneity, a fundamental aspect of cancer, lies at the heart of treatment challenges such as therapy resistance, metastasis, and relapse. Leveraging breakthroughs in single-cell sequencing and artificial intelligence, we are pioneering a novel approach to unlock insights into intra-tumor heterogeneity and develop innovative cancer treatments.
Who founded Cellyrix Therapeutics?
Cellyrix Therapeutics was founded in 2024 by Mordechai Applebaum (CEO), Dganit Bar (CSO), Avishai Gavish (Chief Business Consultant).
What sector is Cellyrix Therapeutics in?
Cellyrix Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Artificial Intelligence, Generative AI, Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is Cellyrix Therapeutics located?
Cellyrix Therapeutics is based in Rehovot, Israel, Center District.